This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Mar 24;139(12):1775-1776.

doi: 10.1182/blood.2021014492.

Do CARs finally hit the CLL road?

Arnon P Kater¹, J Joseph Melenhorst²

Affiliations

PMID: 35323881
DOI: 10.1182/blood.2021014492

Free article

Editorial

Do CARs finally hit the CLL road?

Arnon P Kater et al. Blood. 2022.

Free article

. 2022 Mar 24;139(12):1775-1776.

doi: 10.1182/blood.2021014492.

Authors

Arnon P Kater¹, J Joseph Melenhorst²

Affiliations

¹ University of Amsterdam.
² University of Pennsylvania.

PMID: 35323881
DOI: 10.1182/blood.2021014492

No abstract available

PubMed Disclaimer

Comment on

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Siddiqi T, et al. Blood. 2022 Mar 24;139(12):1794-1806. doi: 10.1182/blood.2021011895. Blood. 2022. PMID: 34699592 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems